Jennifer Berry
Family · Albany, GANPI 1447489117
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $12,041 of the $15,767 with a category attached, or 76.4%. 33 manufacturers reported payments, led by CSL Behring at 26.8% of the total. 2025 is the largest year on record at $6,856, 4.4 times the $1,557 reported in 2021. Among family clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 518 payments — averaging $30.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$4K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- GSK$1K
- AstraZeneca$1K
- Regeneron Healthcare Solutions, Inc.$1K
- AbbVie$810
- plus $5K from 27 others
What the payments were for
- Consulting fees$3,10120%
- Travel & lodging$5704%
- Food & beverage$12,04176%
- Education$560%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 40 | $4,224 |
| Takeda Pharmaceuticals U.S.A., Inc. | 54 | $1,628 |
| GSK | 88 | $1,476 |
| AstraZeneca | 49 | $1,374 |
| Regeneron Healthcare Solutions, Inc. | 51 | $1,364 |
| AbbVie | 28 | $810 |
| Sanofi | 19 | $726 |
| Biocryst US Sales Co., LLC | 25 | $642 |
| Grifols USA, LLC | 32 | $624 |
| Pfizer | 35 | $559 |
| LEO Pharma Inc. | 17 | $378 |
| Amgen | 16 | $358 |
| Novartis | 12 | $249 |
| Octapharma USA, Inc. | 4 | $237 |
| Blueprint Medicines Corporation | 3 | $185 |
| Genentech USA, Inc. | 6 | $169 |
| Pharming Healthcare, Inc. | 7 | $130 |
| Incyte Corporation | 5 | $103 |
| Kaleo, Inc. | 4 | $72 |
| Dermavant Sciences, Inc. | 3 | $64 |
| Boehringer Ingelheim | 3 | $53 |
| Teva Pharmaceuticals USA, Inc. | 3 | $48 |
| Optinose US, Inc. | 2 | $40 |
| Lilly USA, LLC | 2 | $37 |
| Novo Nordisk | 2 | $37 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $28 |
| ADMA Biomanufacturing LLC | 1 | $25 |
| Phathom Pharmaceuticals, Inc. | 1 | $23 |
| Galderma Laboratories, L.p. | 1 | $22 |
| Genentech, Inc. | 1 | $22 |
| Aimmune Therapeutics, Inc. | 1 | $22 |
| Seagen Inc. | 1 | $20 |
| Alk-abello, Inc | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,767 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 12 | $46,307 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 48 | $34,801 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $30,124 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $12,393 |
| XhanceFluticasone Propionate | 14 | $12,180 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $6,323 |
| Azelastine Hcl | 146 | $4,587 |
| Arnuity ElliptaFluticasone Furoate | 13 | $3,641 |
| Fluticasone Propionate | 214 | $2,910 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 98 | $2,440 |
| Levocetirizine Dihydrochloride | 209 | $1,368 |
| Montelukast Sodium | 172 | $1,305 |
| Mometasone Furoate | 11 | $1,013 |
| Ventolin HfaAlbuterol Sulfate | 17 | $944 |
| Famotidine | 61 | $670 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,476 | $46,15868 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,374 | $41,12466 claims |
| Optinose US, Inc.Xhance | $40 | $12,18014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.
Other family in Albany
- Allie McAllisterMarietta$299K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
- Jessica FeehanCanton$51K
- Julia ThorneCanton$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.